Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Why Do People With Epilepsy Get More Infections? (Epi-IRIS)

5. November 2026 aktualisiert von: University of Aberdeen

Epilepsy, Immune Dysfunction and Risk of Infection Study - A Prospective Cohort Study of Immune Dysfunction and Infection Risk With Epilepsy

People with epilepsy are predisposed to having seizures ("fits"), where abnormal electrical activity in the brain disrupts normal brain functioning. It is a common condition with around 1% of the population of Scotland having this condition. They are treated with anti-seizure medications, drugs which reduce the chance of having seizures.

Unfortunately, people with epilepsy are more likely to have severe infections than those without epilepsy and this is known to increase risk of seizures. The reasons for more severe infections in people with epilepsy are unclear, but one factor may be that anti-seizure medications impair the function of the body's immune system, which fights infection. The investigators' previous work looking at residents in the North-East of Scotland showed a link between these medications and risk of infection.

The investigators plan to study people being started on antiseizure medications (ASMs) with a new diagnosis of epilepsy and those already on ASMs with an established diagnosis of epilepsy in NHS Grampian. The investigators will compare with people not taking ASMs in a group of people with a single seizure and in a group of people with migraine.

The investigators will investigate immune function and infection risk with more-detailed information about individual's background, their seizures/epilepsy, other health conditions, and blood tests. The investigators will then do laboratory experiments to determine how ASMs may impair the immune system by looking at the function of types of white blood cells that play an important part in immune functioning.

The investigators also wish to develop statistical tools which can identify an individual's risk of infection when starting ASMs, based on their demographic, medical and social characteristics, to target closer monitoring/changes in treatment to those with higher risk.

This research will allow healthcare professionals to provide better individualised care in terms of which medication to use for treatment, what doses to use and whether blood tests to screen for impaired immune function would be helpful. The aim is that this will lead to reduced risk of infections in people with epilepsy, resulting in better outcomes in this condition.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background:

Epilepsy is a common neurological condition affecting 1% of the population and is associated with a 2.6-fold increased mortality risk, partly due to infection-related deaths. The investigators previously showed that anti-seizure medications (ASMs) are associated with abnormal immune function (hypogammaglobulinemia, lymphopenia, and neutropenia) and increased infection risk, but further work is needed to understand this risk and whether it can be reduced.

Aims:

  1. To clarify the effects of ASM on blood immune parameters
  2. To establish whether ASMs are associated with increased infection rates
  3. To explore potential mechanisms of immune dysfunction with commonly used ASMs
  4. To develop predictive models for infection risk based on clinical and laboratory data
  5. To develop and validate algorithms using routinely collected healthcare data to determine diagnosis of epilepsy, recurrence of seizure and good seizure control.

Protocol/methodology:

The investigators will recruit a cohort of approximately 500 participants: 100 new epilepsy cases and 100 established epilepsy cases (treated with ASMs) and 200-300 first seizures and 0-100 people with migraine (not treated with ASMs) and follow them for 10 years. This will result in an initial cohort of approximately 200 individuals treated with ASMs (new and established epilepsy) and 300 not treated with ASMs (between first seizure and migraine). Using this cohort, the investigators will investigate changes in immune parameters (hypogammaglobulinemia, lymphopenia, neutropenia) in people treated with ASMs. The investigators will then investigate the frequency of infections. These analyses will expand on the investigators' previous work by adjusting for co-morbidities and studying specific types of infection, such as opportunistic infections. The investigators will use routinely collected data to support the information gathered from patients during the study, and to validate the use of this for determining diagnosis of epilepsy and seizure frequency.

The investigators will investigate potential mechanisms of immune system dysfunction with ASMs with in vitro studies of innate immune system activity, including phagocytosis assays, killing assays, and viability assays in cultured macrophages/neutrophils with and without ASMs

The investigators will then develop a prognostic model to identify people taking ASMs who are at high risk of infection who may need monitoring of immune parameters.

Expected outcomes/benefits:

  1. A better understanding of infection risk in those treated with ASMs.
  2. Ability to identify those at high infection risk and intervene to reduce infection-related morbidity/mortality with screening, changing ASMs, or interventions directed at the mechanisms.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

500

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

16 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

N/A

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Resident in an area covered by NHS Grampian neurology service.

Potential participants will have either been reviewed by the neurology team as an inpatient or outpatient.

Beschreibung

Inclusion Criteria:

  1. Adults aged 16 or over

  2. Resident in an area covered by NHS Grampian neurology service

  3. Individuals with:

    1. A diagnosis of first unprovoked (or reflex) seizure; or
    2. A new diagnosis of epilepsy (at least two unprovoked (or reflex) seizures occurring more than 24 hours apart)); or
    3. Established diagnosis of epilepsy; or
    4. A diagnosis of migraine
  4. Able to give informed consent to participate or, if lacking capacity, a reliable Welfare Guardian/Welfare Attorney/Nearest Relative can give consent on behalf of the participant.

Definition of established epilepsy in this context:

  1. The individual was diagnosed with epilepsy prior to the consultation at which the clinician referred them to the research team; or
  2. When a potential participant is identified from a previous clinic consultation, they already have a diagnosis of epilepsy.

Exclusion Criteria:

  1. Functional (non-epileptic) seizures without epileptic seizures or migraine. If the patient has both epileptic and functional seizures, or migraine and functional seizures, they would be eligible for inclusion, provided they meet the other criteria.

  2. Acute symptomatic seizure(s) without previous or subsequent unprovoked seizure(s) (e.g. due to head trauma, severe infection, significant electrolyte abnormality, alcohol withdrawal) would be an exclusion from the first seizure/epilepsy group.

  3. First seizure group:

    a) Those taking or are planned to be started on antiseizure medication(s)

  4. New diagnosis of epilepsy group:

    1. Those not planned to be started on an antiseizure medication
    2. Those taking, or are planned to be started on, two or more antiseizure medications
    3. Those already taking an antiseizure medication at the time of their new diagnosis of epilepsy
  5. Established epilepsy group:

    1. Those taking, or are planned to be started on, two or more antiseizure medications
    2. Those not taking an antiseizure medication, even if planned to be started on an antiseizure medication
  6. Migraine control group:

    1. Receiving treatment with antiseizure medications; or

    2. Receiving immunosuppressive* treatment for another condition; or

    3. Medical history of single unprovoked seizure or epilepsy

      • Exclusion due to immunosuppression increasing risk of immune dysfunction. Immunosuppression is not an exclusion criterion for first seizure/epilepsy groups as immunosuppression will be used as a variable for other analyses, including risk prediction analyses.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Exposed

Individuals taking antiseizure medications

Antiseizure medications prescribed as routine care

Andere Namen:
  • Antiseizure medication
Unexposed

Individuals not taking antiseizure medications

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Infections
Zeitfenster: During a 10 year period from the time of enrolment

Clinically significant rates of infection (community antimicrobial prescriptions or hospital admissions with infection)

During a 10 year period from the time of enrolment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Blood immune system parameters
Zeitfenster: During a 10 year period from the time of enrolment

Abnormal level of blood immune system parameters (white blood cell counts, immunoglobulins, lymphocyte subsets)

During a 10 year period from the time of enrolment
Experimental laboratory tests
Zeitfenster: Blood obtained during enrolment and/or 6 months after enrolment

In vitro macrophage and/or neutrophil functioning with exposure to common ASMs (carbamazepine, lamotrigine, levetiracetam, phenytoin, sodium valproate)

Blood obtained during enrolment and/or 6 months after enrolment
Prediction of infection
Zeitfenster: During a 10 year period from the time of enrolment

A prognostic model (a statistical tool) that can be used to predict infection frequency in those being started on ASMs.

During a 10 year period from the time of enrolment
Validated algorithm
Zeitfenster: During a 10 year period from the time of enrolment

Validated algorithms using routinely collected healthcare data to i) identify diagnoses of epilepsy; ii) measure seizure recurrence and iii) good seizure control.

During a 10 year period from the time of enrolment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. November 2026

Primärer Abschluss (Geschätzt)

1. Mai 2038

Studienabschluss (Geschätzt)

1. Mai 2038

Studienanmeldedaten

Zuerst eingereicht

21. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Oktober 2026

Zuerst gepostet (Tatsächlich)

29. Oktober 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 26/SS/0081-IRAS-367495
  • GCA25219 (Andere Zuschuss-/Finanzierungsnummer: NHS Grampian Charities)
  • 2-006-26 (Andere Kennung: University of Aberdeen - Sponsor Reference Number)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .